NextCure
NXTC
NextCure (NXTC) news
Recent news
Xcellon Biologics: Co acquires GMP manufacturing facility from NextCure
AInvest Wire · Aug 10, 2026NextCure - stockholders to receive CVR for 90% of net proceeds from pipeline monetization for two years post-closing
AInvest Wire · Jul 14, 2026NextCure - Avere to pay Hansoh $120 mln upfront, up to $2.18 bln in milestones, plus royalties for AVR-1 ex-China rights
NextCure, Inc. (Nasdaq: NXTC) has entered into a licensing agreement with Hansoh Pharmaceutical Group for the global rights to AVR-1, excluding the Greater China region, in a deal valued at up to $2.3 billion. Under the terms of the agreement, NextCure will pay Hansoh $120 million upfront, with…
AInvest Wire · Jul 14, 2026NextCure and Avere Therapeutics announce merger to advance once-weekly oral IL-23 therapy
AInvest Wire · Jul 14, 2026NextCure Publishes Non-Clinical Data Defining The Mechanism Of Action For NC525, A Novel LAIR-1 Antibody For AML
AInvest Wire · Nov 15, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.